| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
|
Goldschmidt, Hartmut
|
|
|
9 |
11 |
p. e810-e821
|
artikel
|
| 2 |
Blueprint for greater security of immunoglobulins for patients in Canada
|
Sher, Graham D
|
|
|
9 |
11 |
p. e804-e805
|
artikel
|
| 3 |
Burning out—whose responsibility is it?
|
Kerep, Ana Zelić
|
|
|
9 |
11 |
p. e806
|
artikel
|
| 4 |
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
|
Lonial, Sagar
|
|
|
9 |
11 |
p. e822-e832
|
artikel
|
| 5 |
Iberdomide with dexamethasone: a new backbone for myeloma treatment?
|
Rodriguez-Otero, Paula
|
|
|
9 |
11 |
p. e799-e801
|
artikel
|
| 6 |
Iron deficiency anaemia—an ongoing challenge
|
The Lancet Haematology,
|
|
|
9 |
11 |
p. e797
|
artikel
|
| 7 |
Isolated IgG4-related disease of the left maxillary antrum
|
Ramani, Pratibha
|
|
|
9 |
11 |
p. e862
|
artikel
|
| 8 |
Maximising response depth is important in multiple myeloma
|
Chen, Xiaoyi
|
|
|
9 |
11 |
p. e798-e799
|
artikel
|
| 9 |
Place-of-care manufacturing of gene therapies
|
Adair, Jennifer E
|
|
|
9 |
11 |
p. e807-e808
|
artikel
|
| 10 |
Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study
|
de Vos, Thijs W
|
|
|
9 |
11 |
p. e844-e853
|
artikel
|
| 11 |
Prioritising health equity alongside donation safety
|
Fingrut, Warren B
|
|
|
9 |
11 |
p. e802-e803
|
artikel
|
| 12 |
Prioritising health equity alongside donation safety – Authors' reply
|
Koh, Mickey B C
|
|
|
9 |
11 |
p. e803-e804
|
artikel
|
| 13 |
Rahul Bhargava: making bone marrow transplantation accessible in India
|
Wilkinson, Emma
|
|
|
9 |
11 |
p. e809
|
artikel
|
| 14 |
Should unrelated haematopoietic progenitor cell donors be tested for CD36 in Japan?
|
Sato, Tomohiko
|
|
|
9 |
11 |
p. e802
|
artikel
|
| 15 |
The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA
|
Kantarjian, Hagop
|
|
|
9 |
11 |
p. e854-e861
|
artikel
|
| 16 |
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
|
Benjamin, Reuben
|
|
|
9 |
11 |
p. e833-e843
|
artikel
|
Tijdschrift beschrijving